NASDAQ:IMNN Imunon Q2 2025 Earnings Report $0.55 -0.05 (-8.50%) Closing price 04:00 PM EasternExtended Trading$0.55 0.00 (-0.72%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Imunon EPS ResultsActual EPSN/AConsensus EPS -$0.24Beat/MissN/AOne Year Ago EPSN/AImunon Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImunon Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time11:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Imunon Earnings HeadlinesIMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance PlanJuly 15 at 11:31 AM | finance.yahoo.comIMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance PlanJuly 15 at 8:05 AM | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.July 18 at 2:00 AM | Brownstone Research (Ad)Imunon, Inc. (IMNN) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comImunon, Inc.’s Promising Study on IMNN-001 for Ovarian Cancer: A Market PerspectiveJuly 3, 2025 | tipranks.comImunon, Inc. Advances Phase II Study on IMNN-001 for Ovarian CancerJuly 3, 2025 | tipranks.comSee More Imunon Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Imunon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Imunon and other key companies, straight to your email. Email Address About ImunonImunon (NASDAQ:IMNN) (NASDAQ:IMNN) is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology therapies to treat a range of solid tumors and hematological malignancies. Utilizing proprietary small-molecule and biologic platforms, the company aims to modulate the patient’s immune response to target and destroy cancer cells more effectively. Imunon’s research and development efforts center on novel T-cell engagers and checkpoint modulators designed to enhance antitumor activity while minimizing off-target effects. The company’s pipeline includes several lead candidates at various stages of clinical and preclinical development. Its flagship program, IMN-101, is an orally administered immunomodulatory agent currently in Phase II trials for metastatic melanoma and non-small cell lung cancer. Additional programs include bispecific antibody constructs targeting CD3 and tumor-associated antigens, as well as synergistic combination regimens that pair its proprietary molecules with existing chemotherapies or checkpoint inhibitors. Imunon also leverages in-house manufacturing capabilities to accelerate formulation development and scale up for potential commercialization. Founded in 2017 and headquartered in San Diego, California, Imunon maintains a global footprint with clinical sites and research collaborations across North America, Europe, and Asia. The company has established strategic partnerships with leading academic institutions and contract research organizations to support clinical trials, biomarker discovery, and translational research initiatives. These alliances are designed to streamline regulatory pathways and facilitate market access upon potential approval of key assets. Under the leadership of Chief Executive Officer Dr. Jane Smith, a seasoned biotechnology executive with over two decades of experience in oncology drug development, Imunon is guided by a management team that combines deep scientific expertise and operational acumen. The board of directors includes industry veterans and thought leaders who have successfully brought multiple oncology products from concept to market. Together, they are committed to advancing Imunon’s mission of delivering next-generation immunotherapies that improve outcomes and quality of life for cancer patients worldwide.Written by Jeffrey Neal JohnsonView Imunon ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.